×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:AMRN

Amarin Stock Forecast, Price & News

$1.92
-0.07 (-3.52%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.90
$2.01
50-Day Range
$1.13
$3.27
52-Week Range
$1.11
$5.97
Volume
2.67 million shs
Average Volume
4.14 million shs
Market Capitalization
$762.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
30 days | 90 days | 365 days | Advanced Chart

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock Forecast (MarketRank)

Overall MarketRank

2.24 out of 5 stars

Medical Sector

331st out of 1,418 stocks

Pharmaceutical Preparations Industry

140th out of 679 stocks

Analyst Opinion: 3.9Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Amarin logo

About Amarin (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock News Headlines

Amarin (NASDAQ:AMRN) Stock Price Down 4.5%
Amarin (NASDAQ:AMRN) Shares Gap Up to $1.78
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Company Calendar

Last Earnings
5/04/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+30.2%
Consensus Rating
Hold
Rating Score (0-4)
1.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$7.73 million
Pretax Margin
-3.00%

Debt

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.06 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
393,435,000
Market Cap
$762.26 million
Optionable
Optionable
Beta
2.12

Social Links















Amarin Frequently Asked Questions

Should I buy or sell Amarin stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amarin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View analyst ratings for Amarin
or view top-rated stocks.

What is Amarin's stock price forecast for 2022?

6 analysts have issued 1 year price targets for Amarin's shares. Their AMRN stock forecasts range from $1.50 to $3.00. On average, they expect Amarin's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

How has Amarin's stock performed in 2022?

Amarin's stock was trading at $3.37 at the start of the year. Since then, AMRN stock has decreased by 43.0% and is now trading at $1.92.
View the best growth stocks for 2022 here
.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.06. The biopharmaceutical company had revenue of $94.60 million for the quarter, compared to analysts' expectations of $128.21 million. Amarin had a negative net margin of 4.15% and a negative trailing twelve-month return on equity of 1.31%. The company's quarterly revenue was down 33.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.03 earnings per share.
View Amarin's earnings history
.

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • Mr. Karim Mikhail, Pres, CEO & Director (Age 51, Pay $1.19M)
  • Mr. Michael W. Kalb CPA, CFO, Sr. VP & Assistant Sec. (Age 51, Pay $685.88k)
  • Dr. Steven B. Ketchum Ph.D., Pres of R&D, Exec. VP and Chief Scientific Officer (Age 57, Pay $827.62k)
  • Mr. Jason M. Marks J.D., Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. (Age 46, Pay $626.07k)
  • Mr. Aaron D. Berg, Exec. VP & Pres of U.S. (Age 59, Pay $745.52k)
  • Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
  • Alina Kolomeyer, Director of Communications
  • Mr. Alan J. Wills B.A., BA (Zoology), M.B.A., MBA, Exec. VP of Corp. Bus. Devel. (Age 59)
  • Ms. Donna Pasek, Sr. VP of HR
  • Dr. Keith Wood, Head of R&D Operations

What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sarissa Capital Management LP (6.05%), Eversept Partners LP (2.26%), Clearbridge Investments LLC (1.21%), Fairmount Funds Management LLC (1.04%), Kynam Capital Management LP (0.58%) and 13D Management LLC (0.51%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Lars Ekman, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends for Amarin
.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Group One Trading L.P., Jane Street Group LLC, Edgestream Partners L.P., IMC Chicago LLC, Evanson Asset Management LLC, Williams Jones Wealth Management LLC., and Handelsbanken Fonder AB. Company insiders that have sold Amarin company stock in the last two years include John F Thero, Michael Wayne Kalb, and Steven B Ketchum.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which major investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, 13D Management LLC, Fairmount Funds Management LLC, Goldman Sachs Group Inc., Kynam Capital Management LP, M Holdings Securities Inc., Commonwealth Equity Services LLC, and LCM Capital Management Inc. Company insiders that have bought Amarin stock in the last two years include David M Stack, Joseph S Zakrzewski, and Olsen Per Wold.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.92.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $762.26 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.050010) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 560 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More

When was Amarin founded?

Amarin was founded in 1991.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for Amarin is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].

This page (NASDAQ:AMRN) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.